skip to main content
Idioma:
Resultados 1 2 3 4 5 next page
Refinado por: Base de dados/Biblioteca: ClinicalKey remover Base de dados/Biblioteca: Wiley Online Library Journals remover MEDLINE Complete (EBSCOhost) remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Economic Evaluation Of Omalizumab Add-On Therapy In Patients With Uncontrolled Severe Allergic Asthma From The Private Health Care System Perspective In Brazil
Economic Evaluation Of Omalizumab Add-On Therapy In Patients With Uncontrolled Severe Allergic Asthma From The Private Health Care System Perspective In Brazil
Material Type:
Artigo 		Adicionar ao Meu Espaço

Economic Evaluation Of Omalizumab Add-On Therapy In Patients With Uncontrolled Severe Allergic Asthma From The Private Health Care System Perspective In Brazil

Suzuki, C ; Santoni, N.B ; Silva, N.L

Value in health, 2013-05, Vol.16 (3), p.A234-A234 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
2
Estimating The Budget Impact Of Adding Omalizumab To Standard Therapy In Patients With Uncontrolled Severe Allergic Asthma From Private Health Care System Perspective In Brazil
Estimating The Budget Impact Of Adding Omalizumab To Standard Therapy In Patients With Uncontrolled Severe Allergic Asthma From Private Health Care System Perspective In Brazil
Material Type:
Artigo 		Adicionar ao Meu Espaço

Estimating The Budget Impact Of Adding Omalizumab To Standard Therapy In Patients With Uncontrolled Severe Allergic Asthma From Private Health Care System Perspective In Brazil

Suzuki, C ; Santoni, N.B ; Silva, N.L

Value in health, 2013-05, Vol.16 (3), p.A232-A233 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
3
PRS42 - COST-EFFECTIVENESS OF INDACATEROL/GLYCOPYRRONIUM IN THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN BRAZIL
PRS42 - COST-EFFECTIVENESS OF INDACATEROL/GLYCOPYRRONIUM IN THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN BRAZIL
Material Type:
Artigo 		Adicionar ao Meu Espaço

PRS42 - COST-EFFECTIVENESS OF INDACATEROL/GLYCOPYRRONIUM IN THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN BRAZIL

Tozato, C. ; Suzuki, C.

Value in health, 2018-10, Vol.21, p.S411-S411 [Periódico revisado por pares]

Elsevier Inc

Texto completo disponível

Citações Citado por
4
PRS26 Economic Evaluation of Omalizumab in Patients With Uncontrolled Severe Allergic Asthma From the Public Payer Perspective in Brazil
PRS26 Economic Evaluation of Omalizumab in Patients With Uncontrolled Severe Allergic Asthma From the Public Payer Perspective in Brazil
Material Type:
Artigo 		Adicionar ao Meu Espaço

PRS26 Economic Evaluation of Omalizumab in Patients With Uncontrolled Severe Allergic Asthma From the Public Payer Perspective in Brazil

Suzuki, C ; Pepe, C ; Silva, N.L

Value in health, 2012-11, Vol.15 (7), p.A564-A564 [Periódico revisado por pares]

Elsevier Inc

Texto completo disponível

Citações Citado por
5
PND40 Cost-Utility Analysis of Fingolimod in Brazilian Patients With Multiple Sclerosis
PND40 Cost-Utility Analysis of Fingolimod in Brazilian Patients With Multiple Sclerosis
Material Type:
Artigo 		Adicionar ao Meu Espaço

PND40 Cost-Utility Analysis of Fingolimod in Brazilian Patients With Multiple Sclerosis

Silva, N.L ; Takemoto, M.L.S ; Cruz, R.B ; Suzuki, C

Value in health, 2012-11, Vol.15 (7), p.A552-A553 [Periódico revisado por pares]

Elsevier Inc

Texto completo disponível

Citações Citado por
6
PRS15 Estimating the Budget Impact of Introducing Indacaterol in the Treatment of Chronic Obstructive Pulmonary Disease (COPD) from the Brazilian Public Health Care System (SUS) Perspective
PRS15 Estimating the Budget Impact of Introducing Indacaterol in the Treatment of Chronic Obstructive Pulmonary Disease (COPD) from the Brazilian Public Health Care System (SUS) Perspective
Material Type:
Artigo 		Adicionar ao Meu Espaço

PRS15 Estimating the Budget Impact of Introducing Indacaterol in the Treatment of Chronic Obstructive Pulmonary Disease (COPD) from the Brazilian Public Health Care System (SUS) Perspective

Suzuki, C ; Silva, N.L

Value in health, 2011, Vol.14 (7), p.A489-A490 [Periódico revisado por pares]

Elsevier Inc

Texto completo disponível

Citações Citado por
7
PRS14 Estimating the Budget Impact of Introducing Indacaterol in the Treatment Of Chronic Obstructive Pulmonary Disease (COPD) from the Public Payer Perspective in SÃo Paulo
PRS14 Estimating the Budget Impact of Introducing Indacaterol in the Treatment Of Chronic Obstructive Pulmonary Disease (COPD) from the Public Payer Perspective in SÃo Paulo
Material Type:
Artigo 		Adicionar ao Meu Espaço

PRS14 Estimating the Budget Impact of Introducing Indacaterol in the Treatment Of Chronic Obstructive Pulmonary Disease (COPD) from the Public Payer Perspective in SÃo Paulo

Suzuki, C ; Silva, N.L

Value in health, 2011, Vol.14 (7), p.A489-A489 [Periódico revisado por pares]

Elsevier Inc

Texto completo disponível

Citações Citado por
8
PRS31 Economic Evaluation of Indacaterol in Chronic Obstructive Pulmonary Disease (COPD) from the Public Payer Perspective in Brazil
PRS31 Economic Evaluation of Indacaterol in Chronic Obstructive Pulmonary Disease (COPD) from the Public Payer Perspective in Brazil
Material Type:
Artigo 		Adicionar ao Meu Espaço

PRS31 Economic Evaluation of Indacaterol in Chronic Obstructive Pulmonary Disease (COPD) from the Public Payer Perspective in Brazil

Suzuki, C ; Silva, N.L

Value in health, 2011, Vol.14 (7), p.A493-A493 [Periódico revisado por pares]

Elsevier Inc

Texto completo disponível

Citações Citado por
9
PRS5 - Estimating the Financial Impact of Introducing Glycopyrronium Bromide in the Treatment of Chronic Obstructive Pulmonary Disease (Copd) From the Perspective of Public Payer of São Paulo (Sp) – Brazil
PRS5 - Estimating the Financial Impact of Introducing Glycopyrronium Bromide in the Treatment of Chronic Obstructive Pulmonary Disease (Copd) From the Perspective of Public Payer of São Paulo (Sp) – Brazil
Material Type:
Artigo 		Adicionar ao Meu Espaço

PRS5 - Estimating the Financial Impact of Introducing Glycopyrronium Bromide in the Treatment of Chronic Obstructive Pulmonary Disease (Copd) From the Perspective of Public Payer of São Paulo (Sp) – Brazil

Suzuki, C ; Lopes, N

Value in health, 2017-10, Vol.20 (9), p.A888-A888 [Periódico revisado por pares]

Elsevier Inc

Texto completo disponível

Citações Citado por
10
PSY11 - Budget Impact of Introducing Secukinumab In The Treatment of Moderate-To-Severe Plaque Psoriasis From The Private Payer Perspective In Brazil
PSY11 - Budget Impact of Introducing Secukinumab In The Treatment of Moderate-To-Severe Plaque Psoriasis From The Private Payer Perspective In Brazil
Material Type:
Artigo 		Adicionar ao Meu Espaço

PSY11 - Budget Impact of Introducing Secukinumab In The Treatment of Moderate-To-Severe Plaque Psoriasis From The Private Payer Perspective In Brazil

Suzuki, C ; Lopes, N

Value in health, 2017-10, Vol.20 (9), p.A891-A891 [Periódico revisado por pares]

Elsevier Inc

Texto completo disponível

Citações Citado por
Resultados 1 2 3 4 5 next page

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.